AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17446337
Drug: Denufosol tetrasodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denufosol tetrasodium (20, 40, or 60 mg) administered three times daily for 28 days
Trial: 17446337
Drug: Placebo (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline) administered three times daily for 28 days
Trial: 9677789
Drug: Ranitidine 50
RxNorm normalized name: ranitidine 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 50 mg e.v. every six hours
Trial: 7673950
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose intravenous immunoglobulin (IVIg) treatment (0.4 g/kg for five consecutive days)
Trial: 2405864
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (FA) supplementation (1 mg daily) during low-dose methotrexate (MTX) therapy (median dose 7.5 mg/week)
Trial: 2405864
Drug: Placebo (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (control group) during low-dose methotrexate (MTX) therapy
Trial: 2405864
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (FA) supplementation (1 mg daily) during low-dose methotrexate (MTX) therapy
Trial: 7431608
Drug: Polyvalent pneumococcal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyvalent pneumococcal vaccine (Pneumovax) at baseline followed by saline placebo four weeks later.
Trial: 7431608
Drug: Saline followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline followed by polyvalent pneumococcal vaccine (Pneumovax).
Trial: 7431608
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (10 volunteers) receiving polyvalent pneumococcal vaccine (Pneumovax).
Trial: 7431608
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (diabetics and controls) receiving the vaccine.
Trial: 31675664
Drug: Donepezil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (10 mg/day for 6 weeks)
Trial: 23046599
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIg) as induction therapy and thereafter as monthly infusions for 26 weeks
Trial: 23046599
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIg) during induction therapy
Trial: 23046599
Drug: Placebo during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo during maintenance therapy
Trial: 20730514
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) replacement therapy for 1 year
Trial: 16858182
Drug: IV/PO moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV/PO moxifloxacin (400 mg q24 hours)
Trial: 16858182
Drug: IV piperacillin-tazobactam
RxNorm normalized name: piperacillin / tazobactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV piperacillin-tazobactam (3.0/0.375 g q6 hours) +/− PO amoxicillin-clavulanate (800 mg/114 mg q12 hours)
Trial: 16858182
Drug: IV piperacillin-tazobactam
RxNorm normalized name: piperacillin / tazobactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV piperacillin-tazobactam +/− PO amoxicillin-clavulanate
Trial: 12482564
Drug: C. pneumoniae‐specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C. pneumoniae‐specific IgG antibody levels
Trial: 12482564
Drug: stratification by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: stratification by antibody levels
Trial: 1869801
Drug: Maltodextrin containing
RxNorm normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltodextrin containing oral rehydration salts (ORS) solution
Trial: 1869801
Drug: WHO recommended
RxNorm normalized name: ALCOHOL 80 mL in 100 mL TOPICAL LIQUID [WHO Recommended Hand Rub]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WHO recommended glucose‐ORS solution
Trial: 6222704
Drug: Benzoyl peroxide
RxNorm normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benzoyl peroxide (5% lotion) applied twice daily for four weeks
Trial: 6222704
Drug: Hexachlorophene (3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexachlorophene (3% colloidal suspension) applied twice daily for four weeks
Trial: 28643570
Drug: Therapeutic instrumental
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic instrumental music performance, 12 individual clinical contacts, twice weekly for six weeks.
Trial: 11561568
Drug: Levofloxacin 300
RxNorm normalized name: Levofloxacine
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin 300 mg daily for 10 days
Trial: 11561568
Drug: Ofloxacin 600
RxNorm normalized name: ofloxacin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 600 mg daily for 10 days
Trial: 6197010
Drug: Vitamin B12
RxNorm normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B12 injection (Control)
Trial: 29536296
Drug: Intraperitoneal paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intraperitoneal paclitaxel (60 mg/m2 on days 0, 14, 21, 28, 42, 49, and 56)
Trial: 29536296
Drug: Intravenous paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous paclitaxel (80 mg/m2 on the same schedule)
Trial: 1869405
Drug: Epinephrine 2%
RxNorm normalized name: Xylocaine with Epinephrine 2%-1:50,000 Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine 2% drops administered twice a day for 2 weeks
Trial: 1869405
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered twice a day for 2 weeks
Trial: 30239552
Drug: High-β-carotene tomato
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-β-carotene tomato juice (30.4 mg of β-carotene)
Trial: 30239552
Drug: High-lycopene tomato
RxNorm normalized name: Tomato
DrugBank: Tomato (DB10573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-lycopene tomato juice (42.5 mg of lycopene)
Trial: 27405054
Drug: Slow infusion
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow infusion feeding (SF)
Trial: 24467807
Drug: Active common
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active common factor based treatment
Trial: 20378197
Drug: Glargine insulin
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Glargine insulin therapy
Trial: 17951477
Drug: Quercetin 730
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin 730 mg/d for 28 d
Trial: 12572723
Drug: Ozonized sunflower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozonized sunflower oil (Oleozon) applied twice per day for 6 weeks
Trial: 12572723
Drug: Ketoconazole cream
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoconazole cream 2% (Nizoral) applied twice per day for 6 weeks
Trial: 2669667
Drug: 4.6 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.6 g/d of omega-3 fatty acids
Trial: 2669667
Drug: corn oil
RxNorm normalized name: Corn Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: corn oil (5.4 g/d linoleic acid)
Trial: 579116
Drug: Tibric acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibric acid (1.5 g daily for 1 year)
Trial: 12430146
Drug: Photodynamic Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic Therapy (PDT)
Trial: 12784346
Drug: Aprepitant plus
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprepitant plus standard therapy (ondansetron 32 mg IV and dexamethasone 20 mg on Day 1; dexamethasone 8 mg twice daily on Days 2-4)
Trial: 12784346
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (ondansetron 32 mg IV and dexamethasone 20 mg on Day 1; dexamethasone 8 mg twice daily on Days 2-4)
Trial: 11006251
Drug: Methazolamide 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methazolamide 1% in cyclodextrin solution
Trial: 8835708
Drug: Paroxetine (PAR),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (PAR), 20 mg/day
Trial: 1445103
Drug: 100 mls
RxNorm normalized name: mepolizumab 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mls of Iopamiro 370 at 1 ml/sec scanning inferosuperiorly
Trial: 1445103
Drug: 50 mls
RxNorm normalized name: chlorothiazide 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mls of Iopamiro 370 at 1 ml/sec scanning inferosuperiorly
Trial: 1445103
Drug: 40 mls
RxNorm normalized name: fidaxomicin 40 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mls hand injected bolus followed by 60 ml pump infusion at 1.3 mls/sec scanning inferosuperiorly
Trial: 31538907
Drug: Curcumin supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin supplementation (2 capsules containing 500 mg of phosphatidylcholine complex of curcumin)
Trial: 31538907
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two 500 mg placebo capsules)
Trial: 23054866
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition (TPN) alone for 28 days
Trial: 15500091
Drug: Chemosensitivity test-guided
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemosensitivity test-guided chemotherapy
Trial: 10917407
Drug: MDMA-125 mg
RxNorm normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA-125 mg
Trial: 10917407
Drug: Amphetamine-40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amphetamine-40 mg
Trial: 10917407
Drug: MDMA-125 mg
RxNorm normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA-125 mg and MDMA-75 mg
Trial: 9207617
Drug: Beta-blockade treatment
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockade treatment
Trial: 9207617
Drug: Non-carvedilol drugs
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-carvedilol drugs
Trial: 8365381
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of zinc as zinc sulphate
Trial: 3510848
Drug: High-dosage oral
RxNorm normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dosage oral metoclopramide (three times 50 mg) with prednisone (three times 25 mg)
Trial: 3510848
Drug: High-dosage oral
RxNorm normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dosage oral metoclopramide (three times 50 mg) without prednisone
Trial: 22549281
Drug: ACE inhibition
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibition (ramipril 5 mg/day)
Trial: 22549281
Drug: ARB (candesartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARB (candesartan 16 mg/day)
Trial: 19513578
Drug: Kyphoplasty (5.56
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kyphoplasty (5.56 +/- 0.62 mL of PMMA)
Trial: 19513578
Drug: Vertebroplasty (4.91
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vertebroplasty (4.91 +/- 0.65 mL of PMMA)
Trial: 12942852
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Lutéran tablet
Trial: 12942852
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg Lutéran tablets (control)
Trial: 10397377
Drug: Sparfloxacin 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sparfloxacin 400 mg
Trial: 10397377
Drug: Sparfloxacin 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sparfloxacin 800 mg
Trial: 10397377
Drug: Sparfloxacin 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sparfloxacin 1200 mg
Trial: 10397377
Drug: Sparfloxacin 1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sparfloxacin 1600 mg
Trial: 8889461
Drug: Pantoprazole 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 120 mg
Trial: 1996921
Drug: Arecoline hydrobromide
RxNorm normalized name: hydrobromic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arecoline hydrobromide (1.0 mg)
Trial: 1996921
Drug: Arecoline hydrobromide
RxNorm normalized name: hydrobromic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arecoline hydrobromide (0.5 mg)
Trial: 6508224
Drug: Anaesthesia without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anaesthesia without volatile agent
Trial: 29523557
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment (including stent retriever thrombectomy, aspiration, and alternative methods)
Trial: 23952739
Drug: Silicone gel
RxNorm normalized name: SILTREX Silicone Gel-Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone gel applied twice a day after stitches removal
Trial: 23952739
Drug: Tretinoin cream
RxNorm normalized name: Tretinoin Cream
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tretinoin cream applied twice a day after stitches removal
Trial: 22610181
Drug: Negative mean
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative mean daily fluid balance
Trial: 15207898
Drug: Toremifene (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toremifene (40 mg per day)
Trial: 15207898
Drug: Post-treatment (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-treatment (1 year after cessation of anti-estrogen)
Trial: 11306202
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens at 0.625 mg/d plus trimonthly medroxyprogesterone acetate at 5 mg/d for 13 days (HRT)
Trial: 10137793
Drug: Prescription drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription drug coverage for new enrollees
Trial: 10137793
Drug: High-cost drugs
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-cost drugs
Trial: 10137793
Drug: Low users
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low users of prescription drugs
Trial: 25264047
Drug: Mekabu (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mekabu (70 g) with a white rice-based breakfast
Trial: 21814218
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of D+EX
Trial: 20819421
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid mixture 0.76 g/day
Trial: 20819421
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid mixture 1.52 g/day
Trial: 20819421
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid mixture 1.52 g/day coadministered with conjugated linoleic acid 1.6 g/day
Trial: 18417744
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa (50% dose increase at randomization)
Trial: 12591556
Drug: Extruded formulated
RxNorm normalized name: Tarsum Reformulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extruded formulated complementary diet from maize and cowpea (L(1)A(1))
Trial: 12591556
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (L(2)N)
Trial: 12711184
Drug: Oseltamivir administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir administered via Enterion capsule (150 mg) to the stomach
Trial: 12711184
Drug: Oseltamivir administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir administered via Enterion capsule (150 mg) to the proximal small bowel
Trial: 12711184
Drug: Oseltamivir administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir administered via Enterion capsule (150 mg) to the distal small bowel
Trial: 12711184
Drug: Oseltamivir administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir administered via Enterion capsule (150 mg) to the ascending colon
Trial: 7835241
Drug: Somatostatin receptor
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin receptor scintigraphy (SRS) for insulinoma
Trial: 7835241
Drug: Somatostatin receptor
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin receptor scintigraphy (SRS) for gastrinoma
Trial: 307546
Drug: L-5-hydroxytryptophan plus
RxNorm normalized name: L-5-HTP
DrugBank: Oxitriptan (DB02959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-5-hydroxytryptophan plus carbidopa
Trial: 31589276
Drug: Usual access
RxNorm normalized name: sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Usual access to medicines (n = 391)
Trial: 31589276
Drug: Free distribution
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free distribution of essential medicines
Trial: 28432326
Drug: T stem
RxNorm normalized name: wheat stem rust extract
DrugBank: Puccinia graminis (DB10706)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T stem cell memory (TSCM) cells identified by phenotypic markers of CD4+ T cells; subsets characterized by IL-2/IL-15 receptors and APOBEC3G anti-viral restriction factors; no specific dosage or duration mentioned.
Trial: 28432326
Drug: Endogenous HSP70
RxNorm normalized name: Indigenous peanut oil
DrugBank: Peanut oil (DB13964)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endogenous HSP70 activation of TSCM and innate immunity pathways; no specific dosage or duration mentioned.
Trial: 8429321
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous immunoglobulin treatment (IVIg) for 5 consecutive days
Trial: 8429321
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous immunoglobulin treatment (IVIg)
Trial: 31808538
Drug: Systemic analgesics
RxNorm normalized name: ANALGESIC CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic analgesics (control group)
Trial: 27393218
Drug: Caphosol mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caphosol mouthwash plus standard oral care
Trial: 27393218
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral care alone
Trial: 25591439
Drug: Dialysate APR
RxNorm normalized name: PrameGel Reformulated Apr 2012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysate APR (2.5% glucose-based peritoneal dialysis solution)
Trial: 25591439
Drug: Ringer solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer solution APR
Trial: 25591439
Drug: Shock group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shock group (conventional intravenous resuscitation)
Trial: 23151341
Drug: Q-1000 (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Q-1000 (1000 mg/d of quercetin, 250 mg/d of vitamin C and 10 mg/d of niacin)
Trial: 23151341
Drug: Q-500 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Q-500 (500 mg/d of quercetin, 125 mg/d of vitamin C and 5 mg/d of niacin)
Trial: 18180897
Drug: Graded therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Graded therapy featuring integrative traditional Chinese and Western medicine including 1.8 g of Xuefuda orally once per day, intravenous dripping of 250 mL of hemostasis mixture twice a day, 1.2 g of clindamycin per day for stage I; Kangyanling intra-articular injection for stage II-III; 25 mg of sodium hyaluronate for stage IV.
Trial: 27921221
Drug: Natalizumab 300
RxNorm normalized name: natalizumab 300 MG in 15 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natalizumab 300 mg every 4 weeks
Trial: 27770397
Drug: Intermittent androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent androgen deprivation therapy (ADT) for 6 months
Trial: 27770397
Drug: Continuous androgen
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous androgen deprivation therapy (ADT) for 36 months
Trial: 23701149
Drug: 200 mcg
RxNorm normalized name: CrM 200 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mcg vaginal misoprostol
Trial: 23701149
Drug: 400 mcg
RxNorm normalized name: Biotin 400 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mcg vaginal misoprostol